公开(公告)号：US20220387347A1

公开(公告)日：2022-12-08

申请号：US17576868

申请日：2022-01-14

Applicant: GW Pharma Limited ,  Otsuka Pharmaceutical Co., Limited

Inventor： Benjamin WHALLEY ,  Claire Williams ,  Gary Stephens ,  Thomas Hill

IPC: A61K31/05 ,  A61K36/185 ,  A61K31/352 ,  A61K31/045 ,  A61K31/353 ,  A61K45/06

Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.

公开(公告)号：US11311498B2

公开(公告)日：2022-04-26

申请号：US14741829

申请日：2015-06-17

Applicant: GW Pharma Limited

Inventor： Geoffrey Guy ,  Stephen Wright ,  Orrin Devinsky

IPC: A61K31/05 ,  A61K31/352 ,  A61K31/19 ,  A61K31/5513 ,  A61K31/195 ,  A61K31/20 ,  A61K31/27 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/496 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K31/165 ,  A61K31/197 ,  A61K31/35 ,  A61K31/36 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61K9/00 ,  A61K9/08 ,  A61K31/444 ,  A61K31/515 ,  A61K31/55

Abstract: The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US20210128657A1

公开(公告)日：2021-05-06

申请号：US16904643

申请日：2020-06-18

Applicant: GW Pharma Limited

Inventor： BRIAN ANTHONY WHITTLE ,  Colin A. Hill ,  Ian R. Flockhart ,  David Victor Downs ,  Peter Gibson ,  Gary William Wheatley

IPC: A61K36/185 ,  A61K31/352 ,  B01D11/02

Abstract: The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS of given purity, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.

公开(公告)号：US20200206184A1

公开(公告)日：2020-07-02

申请号：US16562515

申请日：2019-09-06

Applicant: GW Pharma Limited

Inventor： PHILIP ROBSON ,  Geoffrey Guy

IPC: A61K31/352 ,  A61K31/047 ,  A61K9/00 ,  A61K31/05 ,  A61K36/185 ,  A61K47/10

Abstract: The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV.

公开(公告)号：US10653641B2

公开(公告)日：2020-05-19

申请号：US15757899

申请日：2016-09-08

Applicant: GW Pharma Limited

Inventor： Philip Robson ,  Geoffrey Guy ,  Stephen Wright ,  Emma Cheetham ,  Dominic Schiller

IPC: A61K31/05 ,  A61P25/18 ,  A61K31/496 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/40 ,  A61K31/519 ,  A61K31/554

Abstract: This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat both positive and negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat anhedonia/asociality in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat avolition/apathy in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat disturbance of attention in mental disorders such as schizophrenia and related disorders; or as a monotherapy or as an adjunct therapy to treat one or more distinct sub-domains of negative symptoms selected from: i) avolition/apathy; ii) anhedonia/asociality and iii) disturbance of attention; or as an adjunct therapy to treat cognitive symptoms, particularly working memory, motor speed and executive function in mental disorders such as schizophrenia and related disorders. There may additionally be provided compositions comprising CBD in combination with one or more antipsychotics such as olanzapine and quetiapine. In particular the invention relates to the treatment of schizophrenia or related psychotic disorders, more particularly still those which are considered to be treatment resistant.

公开(公告)号：US20200102131A1

公开(公告)日：2020-04-02

申请号：US16701405

申请日：2019-12-03

Applicant: GW Pharma Limited

Inventor： BRIAN ANTHONY WHITTLE

IPC: B65D65/38 ,  A61K36/534 ,  A61P25/28 ,  B65B31/00 ,  A61K31/352 ,  A61K9/00 ,  A61K31/05 ,  A61K36/185

Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.

公开(公告)号：US10538373B2

公开(公告)日：2020-01-21

申请号：US16417860

申请日：2019-05-21

Applicant: GW Pharma Limited

Inventor： Brian Anthony Whittle

IPC: A61K31/352 ,  A61K31/05 ,  A61K36/185 ,  B65D65/38 ,  B65B31/00 ,  A61K9/00 ,  A61K36/534 ,  A61P25/28

Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.

公开(公告)号：US10179683B2

公开(公告)日：2019-01-15

申请号：US14685707

申请日：2015-04-14

Applicant: GW Pharma Limited

Inventor： Brian Anthony Whittle

IPC: A61K31/05 ,  B65D65/38 ,  A61K9/00 ,  A61K31/352 ,  A61K36/185 ,  B65B31/00

Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.

公开(公告)号：US20180263952A1

公开(公告)日：2018-09-20

申请号：US15763186

申请日：2016-09-29

Applicant: GW Pharma Limited

Inventor： Tamás Bíró ,  Colin Stott ,  Vincenzo Di Marzo

IPC: A61K31/352 ,  A61K31/047 ,  A61K31/191 ,  A61K45/06 ,  A61K9/00

CPC classification number: A61K31/352 ,  A61K9/0014 ,  A61K31/047 ,  A61K31/191 ,  A61K45/06

Abstract: The present invention relates to the use of one or more cannabinoids in the treatment of an inflammatory skin disease. Preferably the one or more cannabinoids are taken from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV). The inflammatory skin disease may be caused by one or more of the following: microbial infection-induced dermatitis; solar dermatitis; atopic dermatitis; and allergic contact dermatitis.

公开(公告)号：US09962341B2

公开(公告)日：2018-05-08

申请号：US15321766

申请日：2015-06-26

Applicant: GW Pharma Limited

Inventor： Colin Stott ,  Marnie Duncan ,  Thomas Hill

IPC: A61K31/05

CPC classification number: A61K31/05 ,  A61K2300/00

Abstract: The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).